Inflammatory Bowel Disease and Thrombosis: A National Inpatient Sample Study

Jessica B. Cohen; Diane M. Comer; Jonathan G. Yabes; Margaret V. Ragni

doi:10.1055/s-0040-1710506

TH Open, Table of Contents

CC BY 4.0 · TH Open 2020; 04(01): e51-e58
DOI: 10.1055/s-0040-1710506

Original Article

Georg Thieme Verlag KG Stuttgart · New York

Inflammatory Bowel Disease and Thrombosis: A National Inpatient Sample Study

Jessica B. Cohen

¹Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States

²University of Pittsburgh, Pittsburgh, Pennsylvania, United States

,

Diane M. Comer

³University of Pittsburgh Center for Research on Health Care Data Center, Pittsburgh, Pennsylvania, United States

,

Jonathan G. Yabes

³University of Pittsburgh Center for Research on Health Care Data Center, Pittsburgh, Pennsylvania, United States

,

Margaret V. Ragni

¹Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States

²University of Pittsburgh, Pittsburgh, Pennsylvania, United States

› Author Affiliations

Abstract

Introduction Thrombosis is more common in inflammatory bowel disease (IBD) patients than the general population, but disease-specific correlates of thrombosis remain unclear.

Methods We performed a retrospective analysis of discharge data from the National Inpatient Sample between 2009 and 2014, using International Disease Classification codes to identify IBD and non-IBD patients with or without thrombosis. We used NIS-provided discharge-level weights to reflect prevalence estimates. Categoric variables were analyzed by Rao-Scott Chi-square test, continuous variables by weighted simple linear regression, and covariates associated with thrombosis by weighted multivariable logistic regression.

Results Thrombosis prevalence in IBD was significantly greater than in non-IBD, 7.52 versus 4.54%, p < 0.0001. IBD patients with thrombosis were older and more likely to be Caucasian than IBD without thrombosis, each p < 0.001. Thrombosis occurred most commonly in the mesenteric vein. Thrombotic risk factors in IBD include surgery, ports, malignancy, dehydration, malnutrition, and steroids at 53.7, 13.2, 13.1, 12.4, 8.9, and 8.2%, respectively. Those with thrombosis had greater severity of illness, 1.42 versus 0.96; length of stay, 7.7 versus 5.5 days; and mortality, 3.8 versus 1.5%; all p < 0.0001. Adjusting for age and comorbidity, odds ratios for predictors of thrombosis included ports, steroids, malnutrition, and malignancy at 1.73, 1.61, 1.34, and 1.13, respectively, while Asian race, 0.61, was protective, each p < 0.001.

Conclusion Thrombosis prevalence is 1.7-fold greater in IBD than non-IBD patients. Adjusting for age and comorbidity, the odds ratio for thrombosis in IBD was 73% higher with ports, 61% higher with steroids, 34% with malnutrition, and 13% with malignancy. Whether long-term anticoagulation would benefit the latter is unknown.

Keywords

inflammatory bowel disease - malignancy - malnutrition - steroids - thrombosis

Full Text

References

References
1 Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126 (06) 1504-1517
2 Kappelman MD, Rifas-Shiman SL, Kleinman K. , et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5 (12) 1424-1429
3 Molodecky NA, Soon IS, Rabi DM. , et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142 (01) 46-54.e42 , quiz e30
4 Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140 (06) 1756-1767
5 Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14 (05) 329-342
6 Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 1 (07) 1343-1348
7 Senchenkova E, Seifert H, Granger DN. Hypercoagulability and platelet abnormalities in inflammatory bowel disease. Semin Thromb Hemost 2015; 41 (06) 582-589
8 Alkim H, Ayaz S, Alkim C, Ulker A, Sahin B. Continuous active state of coagulation system in patients with nonthrombotic inflammatory bowel disease. Clin Appl Thromb Hemost 2011; 17 (06) 600-604
9 Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85 (03) 430-434
10 Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375 (9715): 657-663
11 Kappelman MD, Horvath-Puho E, Sandler RS. , et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60 (07) 937-943
12 Nguyen GC, Bernstein CN, Bitton A. , et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146 (03) 835-848.e6
13 Tinsley A, Naymagon S, Trindade AJ, Sachar DB, Sands BE, Ullman TA. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol 2013; 47 (01) e1-e6
14 Sam JJ, Bernstein CN, Razik R, Thanabalan R, Nguyen GC. Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci 2013; 58 (01) 46-52
15 Databases HCUP; Healthcare Cost and Utilization Project (HCUP). Overview of the National (Nationwide) Inpatient Sample (NIS). Available at: www.hcup-us.ahrq.gov/nisoverview.jsp . Accessed April 20, 3030
16 Kaplan GG, Lim A, Seow CH. , et al. Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World J Gastroenterol 2015; 21 (04) 1251-1260
17 Higgins PDR, Skup M, Mulani PM, Lin J, Chao J. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2015; 13 (02) 316-321
18 Kaddourah O, Numan L, Jeepalyam S, Abughanimeh O, Ghanimeh MA, Abuamr K. Venous thromboembolism prophylaxis in inflammatory bowel disease flare-ups. Ann Gastroenterol 2019; 32 (06) 578-583
19 Egberg MD, Galanko JA, Barnes EL, Kappelman MD. Thrombotic and infectious risks of parenteral nutrition in hospitalized pediatric inflammatory bowel disease. Inflamm Bowel Dis 2019; 25 (03) 601-609
20 Rooden CJ, Tesselaar ME, Osanto S, Rosendaal FR, Huisman MV. Deep vein thrombosis associated with central venous catheters - a review. J Thromb Haemost 2005; 3 (11) 2409-2419
21 Najjar PA, Madenci AL, Zogg CK. , et al. Implementation of a comprehensive post-discharge venous thromboembolism prophylaxis program for abdominal and pelvic surgery patients. J Am Coll Surg 2016; 223 (06) 804-813
22 Morgan K, Boktor M, Ford C. , et al. Venous thromboembolism in IBD: Increased risk for women in CD?. Pathophysiology 2019; 26 (02) 163-168
23 Kim YH, Pfaller B, Marson A, Yim HW, Huang V, Ito S. The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period: A systematic review and meta-analysis. Medicine (Baltimore) 2019; 98 (38) e17309
24 Zakai NA, McClure LA. Racial differences in venous thromboembolism. J Thromb Haemost 2011; 9 (10) 1877-1882
25 Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Cardiol 2000; 85 (11) 1334-1337
26 Faye AS, Hung KW, Cheng K. , et al. Minor hematochezia decreases use of venous thromboembolism prophylaxis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2019 (e-pub ahead of print); Doi: 10.1093/ibd
27 Lobo JL, Garcia-Fuertes JA, Trujillo-Santos J. , et al; RIETE Investigators. Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2018; 30 (05) 526-530
28 Ra G, Thanabalan R, Ratneswaran S, Nguyen GC. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohn's Colitis 2013; 7 (10) e479-e485
29 Nguyen GC, Murthy SK, Bressler B. , et al; CINERGI group. Quality of care and outcomes among hospitalized inflammatory bowel disease patients: a multicenter retrospective study. Inflamm Bowel Dis 2017; 23 (05) 695-701
30 Nguyen GC, Bernstein CN. Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. Am J Gastroenterol 2013; 108 (09) 1486-1495
31 Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Etiopathogenesis, prevention, and treatment of thromboembolism in inflammatory disease. Clin Appl Thromb Hemost 2017; 23 (06) 501-510
32 Sarrazin MS, Rosenthal GE. Finding pure and simple truths with administrative data. JAMA 2012; 307 (13) 1433-1435
33 Haut ER, Pronovost PJ, Schneider EB. Limitations of administrative databases. JAMA 2012; 307 (24) 2589-2590 , author reply 2589–2590